Rise and shine, folks, another busy day is on the way. We can tell, thanks to the cacophonous sounds of the street that are wafting through our window. No matter, we are ensconced as ever in our morning ritual of brewing cups of stimulation — our choice today is ginger spice — and foraging for items of interest. We will, however, take a break to collect our shortest person from an institution of higher learning before returning to our usual routine. So time to get cracking. As threatened, here is a menu of tidbits to help you on your own journey. We hope you have a smashing day and conquer the world. Meanwhile, please do remember to keep in touch. …
The Pfizer (PFE) pill to treat Covid-19 retained its 89% efficacy at preventing hospitalization and death in the full results of a study of 2,246 high-risk patients, STAT writes. Pfizer also reported results from a second study in adults with Covid at normal risk of developing severe disease, a group that included vaccinated people. That study failed to meet its main goal, of increasing the sustained alleviation of self-reported symptoms, at an interim analysis; the study is continuing. Experts breathed a sigh of relief that the Pfizer results held up, though all emphasized the need to more fully examine the data, which were shared in a press release, not a scientific publication. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/pharmalot/2021/12/14/covid19-omicron-pfizer-fda-califf-medicaid/
